Trop2-targeted therapies in solid tumors: advances and future directions

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Trophoblast cell surface antigen 2 (Trop2) is overexpressed in various solid tumors, driving oncogenic signaling pathways.
• Trop2 represents a significant therapeutic target due to its role in cancer progression.

Purpose of the Study:

• To provide a comprehensive review of emerging Trop2-targeted therapies.
• To discuss the design, mechanisms of action (MOAs), and limitations of these therapies.
• To highlight clinical progress and therapeutic efficacy against various tumors.

Main Methods:

• Review of current scientific literature on Trop2-targeted therapies.
• Analysis of clinical trial data for Trop2-targeted agents.
• Discussion of future research directions and precision medicine approaches.

Main Results:

• Significant advancements have been made in Trop2-targeted therapies, particularly antibody-drug conjugates (ADCs).
• These therapies, including ADCs, antibodies, multispecific agents, immunotherapy, cancer vaccines, and small molecular inhibitors, demonstrate therapeutic potential.
• Clinical research shows promising efficacy against Trop2-positive tumors, including triple-negative breast cancer (TNBC).

Conclusions:

• Trop2-targeted therapies have revolutionized treatment outcomes for patients with limited options.
• Further research is needed to enhance understanding of Trop2 biology and optimize combination strategies.
• Precision treatment tailored by Trop2 testing holds promise for improved patient care.